Our Firm’s attorneys hear on a regular basis from individuals who were allegedly injured by the acid concentrate.
New York, NY (PRWEB) October 19, 2014
The federal litigation involving GranuFlo lawsuits (http://www.injurybeacon.com/granuflo-dialysis/lawsuit/) is continuing to move forward in Massachusetts federal court, where more than 2,100 claims have now been filed over the dialysis medication, Bernstein Liebhard LLP reports.
A Case List updated on October 15th shows 2,127 claims now filed over GranuFlo and NaturaLyte in a federal litigation underway in the U.S. District Court, District of Massachusetts. Plaintiffs in these lawsuits accuse the drugs’ manufacturer, Fresenius Medical Care, of failing to adequately warn patients and their doctors about the risk for strokes, heart attacks, cardiac arrest, cardiopulmonary arrest, sudden cardiac death and other life-threatening heart problems to stem from either of the acid concentrates. Given these side effects, plaintiffs allege that GranuFlo and NaturaLyte were designed defectively. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“We are not surprised to see more than 2,100 claims filed in the federal GranuFlo litigation, as our Firm’s attorneys hear on a regular basis from individuals who were allegedly injured by the acid concentrate,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including GranuFlo and NaturaLyte. The Firm is eager to speak with anyone who allegedly suffered serious cardiovascular problems within 72 hours of undergoing a dialysis treatment that used either of the acid concentrates.
Manufactured by Fresenius Medical Care, GranuFlo and NaturaLyte are designed to remove toxins that accumulate during dialysis. The medications became a subject of scrutiny two years ago when the U.S. Food and Drug Administration (FDA) issued a Class I recall that determined their potential to cause cardiovascular injuries to be serious and potentially fatal. Prior to that, dialysis centers owned by GranuFlo and NaturaLyte’s manufacturer, Fresenius Medical Care, administered the drugs in their facilities, as did more than 125,000 customer clinics outside the company’s network.
Plaintiffs in more than 2,100 claims now filed in the U.S. District Court, District of Massachusetts allege problems with Fresenius’ handling of the GranuFlo recall, and accuse the company of withholding vital information about the safety of its products that may have placed thousands of dialysis patients at risk. Shortly after the FDA’s notice about possible problems with GranuFlo and NaturaLyte, the New York Times reported that the regulator was looking into whether the company violated federal regulations in failing to warn dialysis patients about risks that may be associated with its products. An internal memo sent by Fresenius in November 2011 warned of hundreds of patient deaths that occurred in Fresenius centers that administered GranuFlo treatments. Despite their knowledge of dialysis drug problems, the company continued to aggressively market the GranuFlo and NaturaLyte in order to protect their market share, plaintiffs allege.
In addition to thousands of federally-filed dialysis lawsuits filed in Massachusetts, court documents show several more consolidated in a state proceeding underway in Middlesex County Superior Court. More than 3,900 lawsuits are now pending in that litigation, according to recent filings. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O).
Not unlike cases filed in federal court, GranuFlo plaintiffs in Middlesex County allege that an Urgent Product Notification issued in March 2012 by Fresenius was insufficient in warning patients about metabolic alkalosis, a condition referring to elevated pH levels in the blood stream that may derive from an overdose of the acid concentrates, and cause strokes, heart attacks and other cardiovascular injuries.
Dialysis patients who were allegedly harmed by GranuFlo or NaturaLyte may be entitled to take legal action against Fresenius Medical Care. Learn more about filing a GranuFlo lawsuit by visiting Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP